ArticleProceedings of the National Academy of Sciences of the United States of America2025
Synaptobrevin-2 disease variants reveal spatial constraints within the presynaptic active zone.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synaptobrevin-2 Containing Extracellular Vesicles Are Rapidly Incorporated Into Mammalian Neurons via a Dynamin-Dependent Pathway.Journal of neurochemistry · 2026Article
- Lithium as a therapeutic strategy for SNAP25 encephalopathies via modulation of homeostatic plasticity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Regulation of spontaneous neurotransmission and homeostatic synaptic plasticity by synaptotagmin-1 disease variants at the SNARE primary interface.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins drive synaptic transmission in a temporally and spatially precise manner. Recent studies have identified several disease-causing SNARE variants that give rise to developmental and epileptic encephalopathies, defined as SNAREopathies. Here, we investigated nine synaptobrevin-2 (VAMP2) disease-causing variants and uncovered their specific SNARE complex affinity, stability, and conformational deficits that drive dysregulated neurotransmission. The neurotransmission deficits we observed parallel the symptomatic heterogeneity of the patients, with some variants displaying a disproportionate augmentation of spontaneous neurotransmitter release. When we examined the spatial organization of this excessive spontaneous release at nanoscale, we found that SNARE complexes composed of these variants formed exclusively outside of RIM scaffolding, revealing a preserved exclusion zone sparing evoked release from pathophysiology. Taken together with the phenotypes of previously reported disease-causing SNARE variants, these findings reveal shared patterns of aberrant neurotransmission across different SNAREs, highlighting the necessity for a functional classification of SNAREopathies to develop therapeutic interventions. The use of clinically relevant genetic manipulations to challenge the synapse provides mechanistic insight into rare diseases while simultaneously revealing fundamental aspects of synaptic physiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.